SCYX | tickerfilter.com

Fundamental analysis

20%

Profitability 18%

Dept financing 18%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.72%

1 Month

14.79%

3 Months

38.10%

6 Months

-20.36%

1 Year

-2.20%

2 Year

-44.25%

Key data

Stock price

$0.89

P/E Ratio

N/A

DAY RANGE

$0.86 - $0.93

EPS

-$0.17

52 WEEK RANGE

$0.56 - $1.31

52 WEEK CHANGE

$3.93

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

44.664 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

1.48

PUBLIC FLOAT

AVERAGE 10 VOLUME

$441,287

AVERAGE 30 VOLUME

$401,318

Company detail

CEO: Marco Taglietti
Region: US
Website: scynexis.com
Employees: 60
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm, CJSC.

SCYX - SCYNEXIS INC